Related Experiment Video
Updated: Aug 11, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Percutaneous left atrial appendage closure with SeaLA device in non-valvular atrial fibrillation
Zulu Wang1, Huimin Chu2, Xinjing Chen3
1Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Objectives:
The clinical efficacy and safety of a novel left atrial appendage (LAA) occluder of the SeaLA closure system in patients with nonvalvular atrial fibrillation (NVAF) were reported.
Background:
Patients with NVAF are at a higher risk of stroke compared to healthy individuals. Left atrial appendage closure (LAAC) has emerged as a prominent strategy for reducing the risk of thrombosis in individuals with NVAF.
Methods:
A prospective, multicenter study was conducted in NVAF patients with a high risk of stroke.
Results:
The LAAC was successfully performed in 163 patients. The mean age was 66.93 ± 7.92 years, with a mean preoperative CHA2DS2-VASc score of 4.17 ± 1.48. One patient with residual flow >3 mm was observed at the 6-month follow-up, confirmed by TEE. During the follow-up, 2 severe pericardiac effusions were noted, and 2 ischemic strokes were observed. Four device-related thromboses were resolved after anticoagulation treatment. There was no device embolism.
Conclusions:
The LAAC with the SeaLA device demonstrates encouraging feasibility, safety, and efficacy outcomes.
